Jennison Associates LLC increased its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 4.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,276,468 shares of the medical research company's stock after purchasing an additional 57,041 shares during the quarter. Jennison Associates LLC owned 0.99% of NeoGenomics worth $18,828,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors also recently modified their holdings of the company. Arizona State Retirement System raised its stake in NeoGenomics by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 35,739 shares of the medical research company's stock valued at $496,000 after buying an additional 708 shares during the last quarter. Crossmark Global Holdings Inc. lifted its holdings in NeoGenomics by 2.9% in the second quarter. Crossmark Global Holdings Inc. now owns 29,494 shares of the medical research company's stock valued at $409,000 after acquiring an additional 842 shares during the period. Fernwood Investment Management LLC boosted its position in NeoGenomics by 1.0% in the third quarter. Fernwood Investment Management LLC now owns 89,500 shares of the medical research company's stock worth $1,320,000 after purchasing an additional 900 shares during the last quarter. Blue Trust Inc. grew its stake in shares of NeoGenomics by 42.3% during the 3rd quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company's stock valued at $46,000 after purchasing an additional 987 shares during the period. Finally, Oppenheimer Asset Management Inc. increased its position in shares of NeoGenomics by 3.3% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 32,505 shares of the medical research company's stock valued at $451,000 after purchasing an additional 1,030 shares during the last quarter. 98.50% of the stock is owned by hedge funds and other institutional investors.
In other NeoGenomics news, General Counsel Alicia C. Olivo sold 5,175 shares of the stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $15.36, for a total transaction of $79,488.00. Following the completion of the transaction, the general counsel now owns 37,129 shares of the company's stock, valued at $570,301.44. This represents a 12.23 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.30% of the company's stock.
A number of equities analysts recently issued reports on NEO shares. Needham & Company LLC reissued a "buy" rating and issued a $19.00 price objective on shares of NeoGenomics in a report on Wednesday, November 6th. Stephens reissued an "overweight" rating and set a $19.00 price objective on shares of NeoGenomics in a research report on Tuesday, July 30th. Finally, Benchmark restated a "buy" rating and issued a $18.00 price objective on shares of NeoGenomics in a research note on Tuesday, September 24th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, NeoGenomics has an average rating of "Buy" and an average price target of $20.25.
Get Our Latest Analysis on NEO
NEO opened at $16.39 on Friday. NeoGenomics, Inc. has a fifty-two week low of $12.77 and a fifty-two week high of $21.22. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 1.99. The stock has a market cap of $2.10 billion, a price-to-earnings ratio of -25.34 and a beta of 1.19. The firm's fifty day moving average is $14.63 and its 200 day moving average is $14.83.
NeoGenomics (NASDAQ:NEO - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of $0.01 by $0.04. The firm had revenue of $167.80 million during the quarter, compared to analyst estimates of $167.00 million. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The business's quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.06) earnings per share. On average, sell-side analysts forecast that NeoGenomics, Inc. will post -0.17 earnings per share for the current fiscal year.
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.